Developing and commercializing mobile non-invasive neuro diagnostics as a service medical devices

Technology creation and scientific consulting to the pharmaceutical, biomarker, diagnostics. biotechnology, information, and clean technology communities.

Brain Computer Interface Inc is a medical device company dedicated to creating non-invasive assessments of brain health using their MindScope technology.

Neuronostics LLC was an Alzheimer's biomarker discovery and advisory company.

Consultant to MedNest clients on pharmaceutical and medical device scientific and commercial development. Interfaced with both domestic and international clients from Europe. Excellent group.

* Discovered and replicated novel biomarkers by establishing a comprehensive CSF biochemistry biomarker discovery platform.* Initiated and led international collaborations with renowned Alzheimer biomarker thought leaders.* Directed Alzheimer’s Biomarker Team in the discovery, replication and fit-for-purpose use of disease classification, prognosis, and progression biomarkers.* Biology leader of the small molecule beta-secretase inhibitor drug discovery program, including High Throughput Screens, in vivo assessment of pharmacological activity in rodents and primates, co-led project team with medicinal chemistry and PK/Safety assessment colleagues to provide pre-clinical candidates for senior management approval. * Developed and analytically validated free & total Ab assays for immunotherapy plus ten others by directing rhesus and human clinical assay sub-team for MRL Alzheimer’s disease.

Alzheimer's Research

Gene therapy and DNA vaccine

* Founded and incorporated Molecular Combing Research (MCR), a privately-held intangible asset-licensing corporation to develop Molecular Combing technology (Bensimon et al, Science, 1994).* Prepared stock offering document, raised capital, maintained accounting / bank records, etc.* Filed and prosecuted patent applications in the PTO and EPO through the international PCT process.* Litigated in both French Supérieure (TGI) and US federal district courts (E.D. Pa).* European patent EP 0 843 739 issued in 2007, MCR assigned all intellectual property to 3rd party, capital returned to investors.

Princeton, NJ 08540